Turning Point Therapeutics onboards biotech pro as general counsel
Turning Point Therapeutics Inc., a San Diego-based clinical-stage oncology company that develops drugs that address treatment resistance, has hired Annette North as executive vice president and general counsel, effective April 15.
North has been general counsel for a number of biotechnology companies, most recently Kura Oncology and Wellspring Biosciences. At Kura, she was responsible for all legal affairs, including corporate governance and compliance, intellectual property, the company’s financings and public listing on the NASDAQ stock market, and initiation of a pivotal global clinical trial. Before that, North served as senior vice president and general counsel at Ambit Biosciences from initial public offering and initiation of a pivotal global clinical trial through acquisition by Daiichi Sankyo. Prior to Ambit, she was counsel at SGX Pharmaceuticals, Axys Pharmaceuticals, Sequana Therapeutics, and private law firms.
“Annette brings a wealth of experience and depth to our growing management team through 25 years serving biotechnology companies from inception through private and public fundraising, business development, and mergers and acquisitions,” said Athena Countouriotis, M.D., chief executive officer. “On a personal note, I have known Annette for many years and am happy to work with her again as we execute our plans for multiple potentially transformational cancer therapies.”
North earned her Bachelor of Laws and Bachelor of Commerce degrees from Melbourne University in Australia, and is a member of the State Bar of California.